Genmab A/S (NASDAQ:GMAB)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $34.16 and last traded at $34.12, with a volume of 4726 shares. The stock had previously closed at $33.44.
Several research analysts have recently issued reports on the company. Bryan, Garnier & Co lowered Genmab A/S from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 3rd. Barclays reiterated an “overweight” rating on shares of Genmab A/S in a report on Thursday, June 11th. SunTrust Banks lifted their target price on Genmab A/S from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Credit Suisse Group cut Genmab A/S from an “outperform” rating to a “neutral” rating in a report on Thursday, June 25th. Finally, Zacks Investment Research upgraded Genmab A/S from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research note on Thursday, May 28th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $33.33.
The firm has a market capitalization of $22.36 billion and a price-to-earnings ratio of 18.42. The stock has a fifty day moving average of $30.86 and a two-hundred day moving average of $24.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.04 and a quick ratio of 19.04.
Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.04. Genmab A/S had a return on equity of 19.19% and a net margin of 41.69%. The business had revenue of $131.69 million during the quarter, compared to the consensus estimate of $133.04 million. On average, research analysts forecast that Genmab A/S will post 1.05 EPS for the current year.
A number of institutional investors have recently modified their holdings of GMAB. Mercer Global Advisors Inc. ADV bought a new position in shares of Genmab A/S during the 1st quarter worth about $400,000. Waddell & Reed Financial Inc. bought a new position in Genmab A/S in the 1st quarter valued at about $32,637,000. State Street Corp bought a new position in Genmab A/S in the 1st quarter valued at about $849,000. Wells Fargo & Company MN lifted its position in Genmab A/S by 0.4% in the 1st quarter. Wells Fargo & Company MN now owns 940,650 shares of the company’s stock valued at $19,933,000 after acquiring an additional 4,034 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Genmab A/S by 21.1% in the 4th quarter. Bank of America Corp DE now owns 1,128,260 shares of the company’s stock valued at $25,194,000 after acquiring an additional 196,379 shares in the last quarter. Hedge funds and other institutional investors own 4.36% of the company’s stock.
Genmab A/S Company Profile (NASDAQ:GMAB)
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Story: What is a Fiduciary?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.